drugset / Trial / NCT03307915
A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment
Phase 1
Completed
25 enrolled
Janssen Vaccines & Prevention B.V.
Beth Israel Deaconess Medical Center · collabRagon Institute of MGH, MIT and Harvard · collabUS Military HIV Research Program · collab
RandomizedParallel-groupTriple-blindOther
Summary
The primary purpose of this study is to assess safety/tolerability of 2 different prime/boost regimens containing adenovirus serotype 26 (Ad26).Mos4.HIV, Modified Vaccinia Ankara (MVA) -Mosaic or adjuvanted Mosaic and Clade C gp140 in Human immunodeficiency virus type 1 (HIV-1)-infected participants on suppressive antiretroviral treatment (ART).
Timeline
- Start
- 2018-03-05
- Primary completion
- 2021-11-05
- Completion
- 2021-11-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ad26.Mos4.HIV | Vaccine | 5e+10 unknown | Intramuscular |
| Subject | Clade C gp140 | Vaccine | 125 ug | Intramuscular |
| Subject | MVA-Mosaic | Vaccine | 1e+08 unknown | Intramuscular |
| Subject | Mosaic gp140 | Unknown | 125 ug | Intramuscular |